Skip to main navigation Skip to search Skip to main content

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status

  • Guochun Zhang
  • , Chongyang Ren
  • , Cheukfai Li
  • , Yulei Wang
  • , Bo Chen
  • , Lingzhu Wen
  • , Minghan Jia
  • , Kai Li
  • , Hsiaopei Mok
  • , Li Cao
  • , Xiaoqing Chen
  • , Jiali Lin
  • , Guangnan Wei
  • , Yingzhi Li
  • , Yuchen Zhang
  • , Charles M. Balch
  • , Ning Liao

Research output: Contribution to journal › Article › peer-review

Abstract

Background: HER2-low breast cancers were reported to have distinct clinicopathological characteristics from HER2-zero; however, the difference in their genetic features remains unclear. This study investigated the clinical and molecular features of breast tumors according to HER2 status. Methods: We analyzed the clinicopathological and genomic data of 523 Chinese women with breast cancer. Genomic data was generated by targeted next-generation sequencing (NGS) of breast tumor samples using a commercial 520 gene panel. The cohort was stratified according to HER2 status as HER2-zero (n = 90), HER2-low (n = 231), and HER2-positive (n = 202) according to their immunohistochemistry and fluorescence in situ hybridization results. Results: HER2-low breast tumors were enriched with hormone receptor-positive tumors, and who had lower Ki67 expression levels. Genes were differentially mutated across HER2 subgroups. HER2-low tumors had significantly more mutations involved in PI3K-Akt signaling than HER2-positive (p < 0.001) and HER2-zero breast tumors (p < 0.01). HER2-zero tumors had more mutations in checkpoint factors (p < 0.01), Fanconi anemia (p < 0.05), and p53 signaling and cell cycle pathway (p < 0.05) compared to HER2-low breast tumors. Compared with HER2-zero tumors, HER2-low tumors had significantly lower pathological complete response rates after neoadjuvant therapy (15.9% vs. 37.5%, p = 0.042) and proportion of relapsed/progressed patients across follow-up time points (p = 0.031), but had comparable disease-free survival (p = 0.271). Conclusion: Our results demonstrate the distinct clinical and molecular features and clinical outcomes of HER2-low breast tumors.

Original languageEnglish (US)
Article number142
JournalBMC medicine
Volume20
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Breast cancer
  • Genomic alteration
  • HER2-low
  • Human epidermal growth factor receptor 2 (HER2)
  • Next-generation sequencing (NGS)
  • Targeted therapy

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status'. Together they form a unique fingerprint.

Cite this